Investigation Report on China Nifedipine Market, 2010-2019
Description
The incidence of cardiovascular disease has kept going up in China. Currently, 290 million Chinese are suffering from cardiovascular diseases, among which 270 million are suffering from hyper tension, 2.50 million myocardial infarction, 4.5 million heart failure, 5 million pulmonary heart disease, 2.5 million rheumatic heart disease and 5 million congenital heart disease. And one out of five adults suffers from cardiovascular disease which is the leading killer of human health. During the period of 2002-2013, coronary heart disease reported an increase in its incidence. According to the statistics of National Health and Family Planning Commission of the People’s Republic of China, the mortality of coronary heart disease in 2013 was 1008.6/1 million in city and 986.8/1 million in rural areas, both increasing slightly compared with 2012.
The synthesis of nifedipin by Bayer researchers in 1966 opened a new chapter in the treatment of cardiovascular diseases. Developed by Bayer in 1992, nifedipin controlled release tablet (Adalat) has given a new life to nifedipin and created a new dose of hypertension drug. So far, Adalat has benefited hundreds of millions of hypertension patients that include Chinese ones ever since it entered China in 1994.
Nifedipin develops fast after entering China with sales value exceeding 300 million since 2010 and 4 million in 2014. And Bayer (Germany) dominated the market with a share of over 92% in 2014 which still keeps growing. However, Bayer’s market share for sales volume was only about 60% due to its high price. Against the background that more and more people are suffering from cardiovascular diseases at a younger age, nifedipine will enjoy a vast market. And local enterprises can make use of price advantage and enhance R&D so as to take up a share in the market.
Readers can get at least the following information through this report:
The incidence of cardiovascular disease has kept going up in China. Currently, 290 million Chinese are suffering from cardiovascular diseases, among which 270 million are suffering from hyper tension, 2.50 million myocardial infarction, 4.5 million heart failure, 5 million pulmonary heart disease, 2.5 million rheumatic heart disease and 5 million congenital heart disease. And one out of five adults suffers from cardiovascular disease which is the leading killer of human health. During the period of 2002-2013, coronary heart disease reported an increase in its incidence. According to the statistics of National Health and Family Planning Commission of the People’s Republic of China, the mortality of coronary heart disease in 2013 was 1008.6/1 million in city and 986.8/1 million in rural areas, both increasing slightly compared with 2012.
The synthesis of nifedipin by Bayer researchers in 1966 opened a new chapter in the treatment of cardiovascular diseases. Developed by Bayer in 1992, nifedipin controlled release tablet (Adalat) has given a new life to nifedipin and created a new dose of hypertension drug. So far, Adalat has benefited hundreds of millions of hypertension patients that include Chinese ones ever since it entered China in 1994.
Nifedipin develops fast after entering China with sales value exceeding 300 million since 2010 and 4 million in 2014. And Bayer (Germany) dominated the market with a share of over 92% in 2014 which still keeps growing. However, Bayer’s market share for sales volume was only about 60% due to its high price. Against the background that more and more people are suffering from cardiovascular diseases at a younger age, nifedipine will enjoy a vast market. And local enterprises can make use of price advantage and enhance R&D so as to take up a share in the market.
Readers can get at least the following information through this report:
- market size of nifedipine in China
- competitive landscape of nifedipine market in China
- price of nifedipine made by different enterprises in China
- market outlook of nifedipine in China
- manufacturers of cardiovascular drugs
- investors/research institutions interested in Chinese medicine market
1 RELATED CONCEPTS OF NIFEDIPINE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF NIFEDIPINE IN CHINA
2.1 Patent and Approval Information of Nifedipine in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON NIFEDIPINE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR NIFEDIPINE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF NIFEDIPINE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF NIFEDIPINE IN CHINESE HOSPITALS IN 2014
6.1 Shanghai Shyndec Pharmaceutical Co., Ltd (Trade Name: Xinran)
6.2 Bayer (Germany) (Trade Name: Adalat)
6.3 Jiangsu Haici Biological Pharmaceutical Co., Ltd
6.4 Guangdong Medi-world Pharmacy Co. Ltd.
6.5 Shanghai Sine Tianping Pharmaceutical Co., Ltd
6.6 China National Pharmaceutical Industry Corporation Ltd
7 MAJOR MANUFACTURERS OF NIFEDIPINE IN CHINESE MARKET, 2010-2014
7.1 Shanghai Shyndec Pharmaceutical Co., Ltd
7.2 Bayer (Germany)
7.3 Jiangsu Haici Biological Pharmaceutical Co., Ltd
7.4 Guangdong Medi-world Pharmacy Co. Ltd.
7.5 China National Pharmaceutical Industry Corporation Ltd
8 MARKET OUTLOOK OF NIFEDIPINE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Status of Nifedipine in China
Chart Approval Information of Nifedipine in China
Chart Nifedipine Sales in China
Chart Sales Value of Nifedipine in China, 2010-2014
Chart Sales Value of Nifedipine in Some Regions in China, 2010-2014
Chart Sales Volume of Nifedipine in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Made by Bayer (Germany) in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Made by Shanghai Shyndec in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Tablet in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Capsule in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Pill in China, 2010-2014
Chart Price of Nifedipine Made by Shanghai Shyndec Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by Bayer (Germany) in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by Jiangsu Haici Biological Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by Shinan Company in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by Shanghai Sine Tianping Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by China National Pharmaceutical Industry Corporation Ltd in Some Chinese Cities in 2014
COMPANIES MENTIONED
Shanghai Shyndec Pharmaceutical Co., Ltd; Bayer; Jiangsu Haici Biological Pharmaceutical Co., Ltd; Guangdong Medi-world Pharmacy Co. Ltd.; China National Pharmaceutical Industry Corporation Ltd
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF NIFEDIPINE IN CHINA
2.1 Patent and Approval Information of Nifedipine in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON NIFEDIPINE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR NIFEDIPINE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF NIFEDIPINE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF NIFEDIPINE IN CHINESE HOSPITALS IN 2014
6.1 Shanghai Shyndec Pharmaceutical Co., Ltd (Trade Name: Xinran)
6.2 Bayer (Germany) (Trade Name: Adalat)
6.3 Jiangsu Haici Biological Pharmaceutical Co., Ltd
6.4 Guangdong Medi-world Pharmacy Co. Ltd.
6.5 Shanghai Sine Tianping Pharmaceutical Co., Ltd
6.6 China National Pharmaceutical Industry Corporation Ltd
7 MAJOR MANUFACTURERS OF NIFEDIPINE IN CHINESE MARKET, 2010-2014
7.1 Shanghai Shyndec Pharmaceutical Co., Ltd
7.2 Bayer (Germany)
7.3 Jiangsu Haici Biological Pharmaceutical Co., Ltd
7.4 Guangdong Medi-world Pharmacy Co. Ltd.
7.5 China National Pharmaceutical Industry Corporation Ltd
8 MARKET OUTLOOK OF NIFEDIPINE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Status of Nifedipine in China
Chart Approval Information of Nifedipine in China
Chart Nifedipine Sales in China
Chart Sales Value of Nifedipine in China, 2010-2014
Chart Sales Value of Nifedipine in Some Regions in China, 2010-2014
Chart Sales Volume of Nifedipine in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Made by Bayer (Germany) in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Made by Shanghai Shyndec in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Tablet in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Capsule in China, 2010-2014
Chart Sales Value and Market Share of Nifedipine Pill in China, 2010-2014
Chart Price of Nifedipine Made by Shanghai Shyndec Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by Bayer (Germany) in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by Jiangsu Haici Biological Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by Shinan Company in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by Shanghai Sine Tianping Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Nifedipine Made by China National Pharmaceutical Industry Corporation Ltd in Some Chinese Cities in 2014
COMPANIES MENTIONED
Shanghai Shyndec Pharmaceutical Co., Ltd; Bayer; Jiangsu Haici Biological Pharmaceutical Co., Ltd; Guangdong Medi-world Pharmacy Co. Ltd.; China National Pharmaceutical Industry Corporation Ltd
